首页> 外文OA文献 >UGT2B7 promoter variant −840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease

【2h】

UGT2B7 promoter variant −840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease

机译：UGT2B7启动子变体-840g> A有助于镰状细胞疾病患者吗啡的肝脏清除的可变性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Deepika S. Darbari; Ron H.N. van Schaik; Edmund V. Capparelli; Sohail Rana; Robert McCarter; John van den Anker;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants [J] . Chie Emoto, Trevor N. Johnson, Sibylle Neuhoff, CPT: Pharmacometrics & Systems Pharmacology . 2018,第7期

机译：结合肝OCT1和UGT2B7蛋白发育变化的吗啡PBPK模型解释了新生儿和小婴儿的清除率差异
2. P82?Is busulfan clearance different in patients with sickle cell disease (SCD) compared to patients without sickle cell disease? [J] . A Remy, Y Théorêt, M Ansari, Archives of disease in childhood . 2019,第6期

机译：P82？与无镰状细胞病的患者相比，镰状细胞病（SCD）患者的白消安清除率是否不同？
3. Increased clearance of morphine in sickle cell disease: implications for pain management. [J] . Darbari DS, Neely M, van den Anker J, The journal of pain: official journal of the American Pain Society . 2011,第5期

机译：镰状细胞病中吗啡的清除率增加：对疼痛处理的影响。
4. Hydroxyurea Dosage Classification for Sickle Cell Disease Patients [C] . Bikesh Kumar Singh, Hardik Thakkar International Conference on Inventive Computation Technologies . 2021

机译：镰刀细胞病患者的羟基脲剂量分类
5. Human dendritic cells accumulate in lung disease and contribute to serum IgE clearance via FcERI. [D] . Greer, Alexandra. 2013

机译：人树突状细胞在肺部疾病中蓄积并通过FcERI促进血清IgE清除。
6. PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants [O] . Chie Emoto, Trevor N. Johnson, Sibylle Neuhoff, 2018

机译：结合肝OCT1和UGT2B7蛋白的发育变化的吗啡PBPK模型以解释新生儿和小婴儿的清除率差异
7. P82 Is busulfan clearance different in patients with sickle cell disease (SCD) compared to patients without sickle cell disease? [O] . A Remy, Y Théorêt, M Ansari, 2019

机译：P82与没有镰状细胞疾病的患者相比，镰状细胞疾病（SCD）的患者是不同的血红曲线清关吗？
8. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants. Clinical Practice Guideline Number 6; Sickle Cell Disease: Comprehensive Screening and Management in Newborns and Infants. Quick Reference Guide for Clinicians Number 6; Sickle Cell Disease in Newborns and Infants. A Guide for Parents [R] . 1993

机译：镰状细胞病：新生儿和婴儿的筛查，诊断，管理和咨询。临床实践指南第6号;镰状细胞病：新生儿和婴儿的综合筛查和管理。第6号临床医生快速参考指南;新生儿和婴儿的镰状细胞病。家长指南

UGT2B7 promoter variant −840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease

著录项

相似文献

相关主题

期刊订阅